+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Nivolumab"

Nivolumab Market Report 2025 - Product Thumbnail Image

Nivolumab Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
Melanoma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Melanoma Therapeutics - Global Strategic Business Report

  • Report
  • April 2025
  • 162 Pages
  • Global
From
Melanoma Drugs Market Report 2025 - Product Thumbnail Image

Melanoma Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Merkel Cell Carcinoma Treatment Market Report 2025 - Product Thumbnail Image

Merkel Cell Carcinoma Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Malignant Melanoma Treatment Market Report 2025 - Product Thumbnail Image

Malignant Melanoma Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Advanced Melanoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Melanoma - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 180 Pages
  • Global
From
Refractory Metastatic Melanoma - Pipeline Insight, 2025 - Product Thumbnail Image

Refractory Metastatic Melanoma - Pipeline Insight, 2025

  • Clinical Trials
  • March 2025
  • 60 Pages
  • Global
From
Untreated Metastatic or Unresectable Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Untreated Metastatic or Unresectable Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • July 2024
  • 80 Pages
  • Global
From
From
From
From
From
Loading Indicator

Nivolumab is a type of immunotherapy drug used to treat skin cancer. It is a monoclonal antibody that works by blocking the activity of a protein called PD-1, which helps cancer cells evade the body's immune system. Nivolumab is used to treat advanced melanoma, a type of skin cancer, and is approved for use in combination with other drugs. It is also being studied for use in other types of skin cancer, such as squamous cell carcinoma and basal cell carcinoma. Nivolumab is a relatively new drug, and is part of a growing class of immunotherapy drugs that are being used to treat cancer. It has been shown to be effective in treating advanced melanoma, and is being studied for use in other types of skin cancer. Some companies in the Nivolumab market include Bristol-Myers Squibb, Merck, and Roche. Show Less Read more